Instadose Pharma Corp.

Get Top Rated Stock Alerts Active Traders Depend On

Sign Up Today For FREE News Driven Alerts

Canadian Company Becomes The World’s Largest Cannabis Producer

TORONTO, CANADA AND KINSHASA, DEMOCRATIC REPUBLIC OF THE CONGO (DRC) – NOV. 5, 2018 –Canadian based company Instadose Pharma Corp., a wholly owned subsidiary of Excellence Health Group Inc., has become the largest cultivator and pharmaceutical producer of CBD oil. The company received the only licence granted in the DRC to import, export, cultivate and process CBD oil from cannabis.

 

Instadose Pharma is an agricultural and pharmaceutical firm that has had a partnership in traditional growing in the DRC for 5 years.

 

The land under cannabis cultivation is over 100,000 hectares, producing CBD Oil that is GMP certified and pharma grade 99.7% CBD. The company is the largest agricultural grower in the DRC and has a production capacity of 900,000 litres per year, with the largest agricultural presence in the entire DRC.

 

This news has created an unanticipated blow to the market price of the world oil sector. If the company releases oil that is of the highest quality in the world market at a price that devalues the entire index, what will happen to all the licenced producers in this sector?

 

The fact is that DRC production is the most sophisticated facility for oil production. It is not only GMP certified but pharmaceutically accredited with EU Pharmacopeia standards. The leaders in the industry cannot produce oil in any other regions at this price. Instadose Pharma Corp. is also located in Colombia, Argentina and Chile, however, the ideal cost of producing and growing cannabis in the DRC makes South America non-competitive.

 

Grant F. Sanders, CEO, of Excellence Health Group Inc. said: “This is potentially a disruptive flow to the cannabis sector regarding oil production and prices. Our facilities and production will increase accordingly as the world market and prices dictate. We are selling our oil with off-take agreements worldwide including Canada, with the first release of 90,000 litres. Our firm price scale will illustrate the cost to produce in our facility. This will have a rapid effect on the industry for not only producers but the retail customer base. I have great concerns about the reaction of this news with licenced producers and the public investment sector.”

 

Media Contact:
Bash A – Managing Partner
Bash@instadosepharma.com
Tel: (647) 230-0729

Instadose Pharma for the production of drugs in the DRC

Kinshasa – October 24, 2018 – The Deputy Minister of Agriculture, Noël Botakile welcomed this initiative, promising to involve experts from other ministries for technical advice related to this project. A Canadian delegation of Instadose Pharma, led by Mr. Grant F. Sanders, asked Tuesday in Kinshasa, the support of the government in the implementation of a comprehensive project of production of drugs and processing of agricultural products.

 

According to Grant, this program relies heavily on the production of cannabis and other tropical plants, including castor and ginger for the production of drugs. One thousand four hundred (1,400) new products will be put on the market through advanced technology where science is involved on a large scale, he said.

 

Deputy Minister of Agriculture Noël Botakile welcomed this initiative, promising to involve experts from other ministries for technical advice related to this project. It is for him to see if cannabis can be at the origin of pharmaceutical products produced in the DRC. Noel Botakile and Ms. Karina Turbay Schanaid of the Tep Comex company of Brazilian rights, have also signed a memorandum of understanding to pave the way for a memorandum of understanding for the supply of equipment and agricultural inputs.

 

This company will also provide after-sales services for the agricultural sites of Kando and Kasonga, in the province of Lualaba and Kaleka in the province of Kasai Central.

 

Media Contact:
Bash A – Managing Partner
Bash@instadosepharma.com
Tel: (647) 230-0729

About Instadose Pharma

 

 

 

INSTADOSE PHARMA

 

  • Agricultural Innovation food securitization
  • Education
  • Microbial growing Enhancement
  • Aquaponics
  • GMP certified medical Cannabis oil processing facilities
  • Pharma Grade production

 

 

 

 

Medical CBD Oil

 

 

 

 

Pharma Grade Production

 

 

 

 

GMP Certified

 

 

 

 

Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated twenty five hundred dollars for Instadose Pharma Corp. current news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF Instadose Pharma Corp.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Sign Up & Get FREE News Alerts From FNM Today!